Haemopoietic-cell transplantation (HCT) is an intensive therapy used to treat high-risk
haematological malignant disorders and other life-threatening haematological and genetic …

The limiting factor for successful hematopoietic stem cell transplantation (HSCT) is graft-
versus-host disease (GvHD), a post-transplant disorder that results from immune-mediated …

Epithelial regeneration is critical for barrier maintenance and organ function after intestinal
injury. The intestinal stem cell (ISC) niche provides Wnt, Notch and epidermal growth factor …

T cell malignancies represent a group of hematologic cancers with high rates of relapse and
mortality in patients for whom no effective targeted therapies exist. The shared expression of …

Intestinal bacteria may modulate the risk of infection and graft-versus-host disease (GVHD)
after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Allo-HSCT recipients …

Adoptive immunotherapy with regulatory T cells (Tregs) is a promising treatment for allograft
rejection and graft-versus-host disease (GVHD). Emerging data indicate that, compared with …

Posttransplantation cyclophosphamide (PTCy) recently has had a marked impact on human
allogeneic hematopoietic cell transplantation (HCT). Yet our understanding of how PTCy …

The intestinal microbiota is an important modulator of graft-versus-host disease (GVHD),
which often complicates allogeneic hematopoietic stem cell transplantation (allo-HSCT) …

Acute graft-versus-host disease (aGVHD) remains a major limitation of allogeneic stem cell
transplantation (SCT), and severe intestinal manifestation is the major cause of early …

Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex,
and many patients experience treatment delays or cannot be treated at all. Although current …